Intranet
Acces
Contact
Publications
2017
Russier Julie, León Verónica, Orecchioni Marco, Hirata Eri, Virdis Patrizia, Fozza Claudio, Sgarrella Francesco, Cuniberti Gianaurelio, Prato Maurizio, Vázquez Ester, Bianco Alberto, Delogu Lucia G
Few-Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients Article de journal
Dans: Angewandte Chemie (International Ed. in English), vol. 56, no. 11, p. 3014–3019, 2017, ISSN: 1521-3773.
Résumé | Liens | BibTeX | Étiquettes: Acute, cancer therapy, Chronic, Cultured, graphene, Graphite, Humans, I2CT, Immune System, leukemia, Leukocytes, Mononuclear, Myeloid, Myelomonocytic, myelomonocytic leukemia, Nanomaterials, Particle Size, Surface Properties, Team-Bianco, Tumor Cells
@article{russier_few-layer_2017,
title = {Few-Layer Graphene Kills Selectively Tumor Cells from Myelomonocytic Leukemia Patients},
author = {Julie Russier and Verónica León and Marco Orecchioni and Eri Hirata and Patrizia Virdis and Claudio Fozza and Francesco Sgarrella and Gianaurelio Cuniberti and Maurizio Prato and Ester Vázquez and Alberto Bianco and Lucia G Delogu},
doi = {10.1002/anie.201700078},
issn = {1521-3773},
year = {2017},
date = {2017-01-01},
journal = {Angewandte Chemie (International Ed. in English)},
volume = {56},
number = {11},
pages = {3014--3019},
abstract = {In the cure of cancer, a major cause of today's mortality, chemotherapy is the most common treatment, though serious frequent challenges are encountered by current anticancer drugs. We discovered that few-layer graphene (FLG) dispersions have a specific killer action on monocytes, showing neither toxic nor activation effects on other immune cells. We confirmed the therapeutic application of graphene on an aggressive type of cancer that is myelomonocytic leukemia, where the monocytes are in their malignant form. We demonstrated that graphene has the unique ability to target and boost specifically the necrosis of monocytic cancer cells. Moreover, the comparison between FLG and a common chemotherapeutic drug, etoposide, confirmed the higher specificity and toxicity of FLG. Since current chemotherapy treatments of leukemia still cause serious problems, these findings open the way to new and safer therapeutic approaches.},
keywords = {Acute, cancer therapy, Chronic, Cultured, graphene, Graphite, Humans, I2CT, Immune System, leukemia, Leukocytes, Mononuclear, Myeloid, Myelomonocytic, myelomonocytic leukemia, Nanomaterials, Particle Size, Surface Properties, Team-Bianco, Tumor Cells},
pubstate = {published},
tppubtype = {article}
}
In the cure of cancer, a major cause of today's mortality, chemotherapy is the most common treatment, though serious frequent challenges are encountered by current anticancer drugs. We discovered that few-layer graphene (FLG) dispersions have a specific killer action on monocytes, showing neither toxic nor activation effects on other immune cells. We confirmed the therapeutic application of graphene on an aggressive type of cancer that is myelomonocytic leukemia, where the monocytes are in their malignant form. We demonstrated that graphene has the unique ability to target and boost specifically the necrosis of monocytic cancer cells. Moreover, the comparison between FLG and a common chemotherapeutic drug, etoposide, confirmed the higher specificity and toxicity of FLG. Since current chemotherapy treatments of leukemia still cause serious problems, these findings open the way to new and safer therapeutic approaches.
2006
Marmey B, Boix C, Barbaroux J B, Dieu-Nosjean M C, Diebold J, Audouin J, Fridman W H, Mueller C G, Molina T J
CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+C Article de journal
Dans: Hum.Pathol., vol. 37, no. 0046-8177 (Print), p. 68–77, 2006.
Résumé | BibTeX | Étiquettes: Adhesion, Antigen, Antigens, B-Cell, Biological, CD14, Cell Differentiation, CELL SEPARATION, Dendritic Cells, Differentiation, Diffuse, Direct, Expression, Flow Cytometry, Fluorescent Antibody Technique, Gene, GLYCOPROTEIN, Glycoproteins, granulocyte/macrophage-colony, Human, Humans, Immunoenzyme Techniques, Immunohistochemistry, Immunologic, Large B-Cell, leukemia, LYMPH, LYMPH NODE, Lymph Nodes, Lymphadenitis, Lymphoid Tissue, LYMPHOMA, Macrophage, Macrophages, Membrane, Membrane Glycoproteins, metabolism, Monocytes, pathology, Phagocytosis, Receptor, Receptors, SIALOADHESIN, SPLEEN, Team-Mueller, tumor, Tumor Markers
@article{marmey_cd14_2006,
title = {CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+C},
author = {B Marmey and C Boix and J B Barbaroux and M C Dieu-Nosjean and J Diebold and J Audouin and W H Fridman and C G Mueller and T J Molina},
year = {2006},
date = {2006-01-01},
journal = {Hum.Pathol.},
volume = {37},
number = {0046-8177 (Print)},
pages = {68--77},
abstract = {The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs). The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed. Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue. We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169. Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169. Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords. With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL). However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages. When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential. Our observation fits well with the lymph node and host response cluster signatures described in the gene profiling signatures of DLBCL. However, the role of this CD14(+) population that may constitute a microenvironment-related marker of this subgroup of DLBCL remains to be determined},
keywords = {Adhesion, Antigen, Antigens, B-Cell, Biological, CD14, Cell Differentiation, CELL SEPARATION, Dendritic Cells, Differentiation, Diffuse, Direct, Expression, Flow Cytometry, Fluorescent Antibody Technique, Gene, GLYCOPROTEIN, Glycoproteins, granulocyte/macrophage-colony, Human, Humans, Immunoenzyme Techniques, Immunohistochemistry, Immunologic, Large B-Cell, leukemia, LYMPH, LYMPH NODE, Lymph Nodes, Lymphadenitis, Lymphoid Tissue, LYMPHOMA, Macrophage, Macrophages, Membrane, Membrane Glycoproteins, metabolism, Monocytes, pathology, Phagocytosis, Receptor, Receptors, SIALOADHESIN, SPLEEN, Team-Mueller, tumor, Tumor Markers},
pubstate = {published},
tppubtype = {article}
}
The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs). The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed. Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue. We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169. Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169. Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords. With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL). However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages. When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential. Our observation fits well with the lymph node and host response cluster signatures described in the gene profiling signatures of DLBCL. However, the role of this CD14(+) population that may constitute a microenvironment-related marker of this subgroup of DLBCL remains to be determined
2002
Kowal M., Roslinski J., Dmoszynska A., Borzecki A., Borzecka H., Keith G.
Genomic hypomethylation in patients with B-cell chronic lymphocytic leukemia Article de journal
Dans: Acta Haematol Pol, vol. 33, no. 3, p. 323-330, 2002.
Résumé | BibTeX | Étiquettes: Chronic, DNA, GIEGE, leukemia, lymphocytic, Methylation
@article{,
title = {Genomic hypomethylation in patients with B-cell chronic lymphocytic leukemia},
author = { M. Kowal and J. Roslinski and A. Dmoszynska and A. Borzecki and H. Borzecka and G. Keith},
year = {2002},
date = {2002-01-01},
journal = {Acta Haematol Pol},
volume = {33},
number = {3},
pages = {323-330},
abstract = {During the last few years, increasing attention has been paid to the relationship between DNA methylation and cancer. Hypo- or hypermethylation of DNA may result in up or down regulation of genes involved in the pathogenesis of leukemias. In this study we have analyzed DNA methylation in peripheral blood and bone marrow B (CD19+) and T (CD3+) lymphocytes from untreated patients with B-cell chronic lymphocytic leukemia.},
keywords = {Chronic, DNA, GIEGE, leukemia, lymphocytic, Methylation},
pubstate = {published},
tppubtype = {article}
}
During the last few years, increasing attention has been paid to the relationship between DNA methylation and cancer. Hypo- or hypermethylation of DNA may result in up or down regulation of genes involved in the pathogenesis of leukemias. In this study we have analyzed DNA methylation in peripheral blood and bone marrow B (CD19+) and T (CD3+) lymphocytes from untreated patients with B-cell chronic lymphocytic leukemia.
